Open Access
Med Sci (Paris)
Volume 38, Number 5, Mai 2022
Page(s) 457 - 463
Section M/S Revues
Published online 24 May 2022
  1. United Nations, Department of Economic and Social Affairs, Population Division (2019). Contraceptive Use by Method 2019: Data Booklet (ST/ESA/SER.A/435). [Google Scholar]
  2. Sundaram A, Vaughan B, Kost K, et al. Contraceptive failure in the United States: Estimates from the 2006–2010 National Survey of Family Growth. Perspect Sex Reprod Health 2017 ; 49 : 7–16. [CrossRef] [PubMed] [Google Scholar]
  3. Islam MS, Afrin S, Jones SI, Segars J. Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility. Endocr Rev 2020; 41(5) : bnaa012. [CrossRef] [PubMed] [Google Scholar]
  4. Curtis KM, Peipert JF. Long-Acting Reversible Contraception. N Engl J Med 2017 ; 376 : 461–468. [CrossRef] [PubMed] [Google Scholar]
  5. Moreau C, Bohet A, Le Guen M, et al. FECOND Group Unplanned or unwanted? A randomized study of national estimates of pregnancy intentions. Fertil Steril 2014 ; 102 : 1663–1670. [CrossRef] [PubMed] [Google Scholar]
  6. Sundaram A, Vaughan B, Kost K, et al. Contraceptive failure in the United States: estimates from the 2006–2010 National Survey of Family Growth. Perspect Sex Reprod Health 2017 ; 49 : 7–16. [CrossRef] [PubMed] [Google Scholar]
  7. Bongaarts J, O’Neill BC. Global warming policy: is population left out in the cold?. Science 2018 ; 361 : 650–652. [CrossRef] [PubMed] [Google Scholar]
  8. [Google Scholar]
  9. [Google Scholar]
  10. [Google Scholar]
  11. Warasna B, Rajabi N, Mustafa B, et al. Knowledge and attitude of Palestinian women to contraceptives: a cross-sectional study. Lancet 2021; 398 : S45. [CrossRef] [PubMed] [Google Scholar]
  12. Kamijo K, Kataoka Y, Shigemi D. Challenges of accessing emergency contraceptive pills in Japan. BMJ Sex Reprod Health 2021; 47 : 232–3. [CrossRef] [PubMed] [Google Scholar]
  13. [Google Scholar]
  14. Starrs AM, Ezeh AC, Barker G, et al. Accelerate progress—sexual and reproductive health and rights for all: report of the Guttmacher-Lancet Commission. Lancet 2018 ; 391 : 2642–2692. [CrossRef] [PubMed] [Google Scholar]
  15. https/// [Google Scholar]
  16. Ahmed S, Li Q, Liu L, Tsui AO. Maternal deaths averted by contraceptive use: an analysis of 172 countries. Lancet 2012 ; 380 : 111–125. [CrossRef] [PubMed] [Google Scholar]
  17. Cleland J, Bernstein S, Ezeh A, et al. Family planning: the unfinished agenda. Lancet 2006 ; 368 : 1810–1827. [CrossRef] [PubMed] [Google Scholar]
  18. Tran NT, Seuc A, Coulibaly A, et al. Post-partum family planning in Burkina Faso (Yam Daabo): a two group, multi-intervention, single-blinded, cluster-randomised controlled trial. Lancet Glob Health 2019 ; 7 : e1109–e1117. [CrossRef] [PubMed] [Google Scholar]
  19. Toan Tran N, Seuc A, Tshikaya B, et al. Effectiveness of post-partum family planning interventions on contraceptive use and method mix at 1 year after childbirth in Kinshasa, DR Congo (Yam Daabo): a single-blind, cluster-randomised controlled trial. Lancet Glob Health 2020; 8 : e399–e410. [CrossRef] [PubMed] [Google Scholar]
  20. National Institute for Health and Care Excellence. Long-Acting reversible contraception: the effective and appropriate use of long-acting reversible contraception, 2005. https:// [Google Scholar]
  21. Pasvol TJ, McGregor EA, Rait G, Horsfall L. Time trends in contraceptive prescribing in UK primary care 2000–2018: a repeated cross-sectional study. BMJ Sex Repro Health 2021; bmjsrh-2021-201260. [Google Scholar]
  22. Glasier A, Baraitser P, McDaid L, et al. Emergency contraception from the pharmacy 20 years on: a mystery shopper study. BMJ Sex Reprod Health 2021; 47 : 55–60. [CrossRef] [PubMed] [Google Scholar]
  23. Cameron ST, Glasier A, McDaid A, et al. Use of effective contraception following provision of the progestogen-only pill for women presenting to community pharmacies for emergency contraception (Bridge-It): a pragmatic cluster-randomised crossover trial. Lancet 2020; 396 : 1585–94. [CrossRef] [PubMed] [Google Scholar]
  24. Ries Thurman A, Schwartz JL, Brache V, et al. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PLoS One 2018; 13 : e0199778. [CrossRef] [PubMed] [Google Scholar]
  25. Duffy DM. Novel contraceptive targets to inhibit ovulation: the prostaglandin E2 pathway. Hum Reprod Update 2015 ; 21 : 652–670. [CrossRef] [PubMed] [Google Scholar]
  26. Glasier A.. Acceptability of contraception for men: a review. Contraception 2010 ; 82 : 453–456. [CrossRef] [PubMed] [Google Scholar]
  27. Long JE, Lee JE, Blithe DL. Novel Hormonal and Nonhormonal Male Contraceptive Development. J Clin Endocrinol Metab 2021; 106 : e2381–92. [CrossRef] [PubMed] [Google Scholar]
  28. Jain T, Schwarz EB, Mehrotra A. A study of telecontraception. N Engl J Med 2019 ; 381 : 1287–1288. [CrossRef] [PubMed] [Google Scholar]
  29. Sadeghi I, Byrne J, Shakur R, Langer R. Engineered drug delivery devices to address Global Health challenges. J Control Release 2021; 331 : 503–14. [CrossRef] [PubMed] [Google Scholar]
  30. Al Dalaty A, Gualeni B, Coulman S, Birchall J. Models and methods to characterise levonorgestrel release from intradermally administered contraceptives. Drug Deliv Transl Res 2022; 12 : 335–49. [CrossRef] [PubMed] [Google Scholar]
  31. Kirtane AR, Hua T, Hayward A, et al. A once-a-month oral contraceptive. Sci Transl Med 2019; 11 : eaay2602. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.